Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

October 30, 2023

Study Completion Date

December 30, 2024

Conditions
Pancreatic CancerPancreatic Ductal Adenocarcinoma
Interventions
DRUG

NASOX

Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks

Trial Locations (2)

05505

Hallym University Medical Center, Anyang-si

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Hallym University Medical Center

OTHER

lead

Asan Medical Center

OTHER